4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

Dallas, TX, April 01, 2025 (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP intelligence and strategy firm, has released its latest PatentVest Pulse report on brain-computer interfaces (BCIs). Titled "Brain-Computer Interfaces (BCIs): Who's Leading, What They Own, and How IP Will Decide the Future," the report reveals how control over intellectual property—not just innovation—is shaping the future of neurotechnology. Neurological disorders represent one of the fastest-growing and highest-need areas in global healthcare, with millions affected by conditions such as paralysis, epilepsy, stroke, and treatment-resistant depression. As traditional treatments struggle to deliver me

Addison, TX, March 31, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading deep technology companies, today provides an update on operations through and subsequent to the quarter ended December 31, 2024. "We are encouraged by our progress this year in a difficult environment. I'm proud of our team for successfully spinning out another Big Idea in the public markets, for completing our first full year of our clearing and trading platform, and for growing our investor community in this challenging venture market," said Christopher Marlett, CEO and Co-Founder of MDB. "In today's market, where venture capit

Addison, TX, March 24, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading deep technology companies, plans to host a Zoom webinar on Monday March 31, 2025 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full year 2024. A press release detailing these results will be issued prior to the call. Christopher Marlett, CEO and Co-Founder of MDB will lead the call and will be joined by other members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period. Investors can pre-register now for the Zoo

Dallas, TX, March 05, 2025 (GLOBE NEWSWIRE) -- Today, PatentVest, a leading provider of IP Strategy and IP Law services, announces the release of its latest PatentVest Pulse Report, "AI-Driven Data Centers – The Patent Race Reshaping AI Infrastructure." This in-depth analysis explores the rapidly evolving AI data center market, offering valuable insights into the trends, key players, and opportunities shaping the future of AI infrastructure. Enterprise data generation is projected to reach 1.2 million exabytes by 2025, placing unprecedented demands on digital infrastructure. As AI workloads continue to expand, data centers must evolve to support high-performance computing, real-time data

Monrovia, CA, Feb. 21, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ:EXOZ, formerly Invizyne Technologies)) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - and MDB Capital Holdings (NASDAQ:MDBH) - a premier venture platform for breakthrough technology companies - today announced key leadership changes within the eXoZymes board of directors. Mo Hayat has transitioned out of his roles as Chairman of the Board and President of eXoZymes, to focus on new MDB Capital ventures. Edgardo Rayo will join the board on behalf of MDB Capital, making it a full circle moment, as he was the MDB Capital team member who disco

Monrovia, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- eXoZymes, Inc. (NASDAQ:EXOZ) ("eXoZymes") – a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels – today announced that CEO Michael Heltzen will be joined by eXoZymes team members to ring the Nasdaq Stock Market ("Nasdaq") closing bell on Wednesday, February 19, 2025. This comes following a successful initial public offering of common stock at $8 per share, which closed on November 14, 2024. "Our team is thrilled to be ringing the closing bell to commemorate both our initial public offering and our significant progress towards establishing that after synthetic biology (

Rebranding Invizyne Technologies, Inc to eXoZymes Inc.Changing NASDAQ ticker from IZTC to EXOZIntroducing but not trademarking "exozymes" as a new scientific nomenclature Monrovia, California, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc. - a pioneer of AI-engineered enzymes that can sustainably transform feedstock into essential chemicals, medicines, and biofuels, announced a corporate name change to eXoZymes, Inc. ("eXoZymes") and that its common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol of "EXOZ" effective before the market open. No action is required by existing shareholders with respect to the name and ticker symbol c

Monrovia, CA, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc., (NASDAQ:IZTC) ("Invizyne"), a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, announced a corporate name change to eXoZymes, Inc. ("eXoZymes") and an application for a new ticker symbol. The company expects trading under the new ticker symbol of "EXOZ" to begin on February 12, 2025, subject to final approvals. In connection with the corporate name change, Company branding, including the corporate website, will be updated accordingly. No action is required by existing shareholders with respect to the name and

Addison, TX, Jan. 07, 2025 (GLOBE NEWSWIRE) -- PatentVest, a leader in intellectual property (IP) intelligence and strategy, has released its latest report, "Continuous Glucose Monitoring (CGM): An Evolving Innovation Landscape." This in-depth analysis explores the rapidly growing CGM market, offering valuable insights into the trends, key players, and opportunities that are shaping the future of diabetes care. Diabetes is one of the most pressing global health challenges, affecting an estimated 537 million adults worldwide in 2021—a number projected to rise to 783 million by 2045. As the complexity of diabetes management grows, the need for continuous, real-time glucose monitoring has ne

Addison, TX, Nov. 21, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading deep technology companies, today provides an update on operations through and subsequent to the quarter ended September 30, 2024. "Throughout the year, we continued to strengthen our operations to increase our capacity to curate and diligence deep technology ideas that we can ultimately finance and help stand up to become leaders in their technology category," said Christopher Marlett, CEO and Co-Founder of MDB. "At the same time, we deepened and broadened our relationships with our investor community by expanding our self-clearin

Addison, TX, March 24, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading deep technology companies, plans to host a Zoom webinar on Monday March 31, 2025 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full year 2024. A press release detailing these results will be issued prior to the call. Christopher Marlett, CEO and Co-Founder of MDB will lead the call and will be joined by other members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period. Investors can pre-register now for the Zoo

Addison, Texas, Nov. 15, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading deep technology companies, plans to host a Zoom webinar on Thursday November 21, 2024 at 4:30 p.m. Eastern Time to discuss its results for the third quarter 2024. A press release detailing these results will be issued prior to the call. Christopher Marlett, CEO and Co-Founder of MDB will lead the call and will be joined by other members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period. Investors can pre-register now for the Zoo

Addison, TX, Nov. 02, 2023 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, will hold a conference call on Wednesday, November 15, 2023, at 4:30 p.m. Eastern Time to discuss its results for the third quarter ended September 30, 2023. A press release detailing these results will be issued prior to the call.  Christopher Marlett, CEO and Co-Founder of MDB will lead the call and will be joined by other members of the management team to review recent developments, ongoing initiatives, anticipated 2024 milestone